| Description | The mAb is a neutralizing IgG against SARS-CoV-2 Spike S1 protein. The epitope of this antibody belongs to the RBD-2 community (Class 1) and has extensive overlap with the ACE2-binding site on the RBM. The antibody is capable of neutralizing live SARS-CoV-2 wild type, Beta, Delta, Omicron BA.1 and Omicron BA.2 variants. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (WT, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, BA.3 and XD subvariant) |
| Epitope | The antibody binds to the residues Y449, L455, F456, N477, V483, A484, G485, F486, N487, C488, Y489, and R493 on the receptor-binding motif (RBM). |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | This antibody's neutralizing capacity was tested by Neutralization assay and the results demonstrated that IC₅₀ value is below 150 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
